Mark W. Hahn - 11 Nov 2024 Form 4 Insider Report for Verona Pharma plc (VRNA)

Signature
/s/ Andrew Fisher, Attorney-in-Fact for Mark Hahn
Issuer symbol
VRNA
Transactions as of
11 Nov 2024
Net transactions value
-$12,000
Form type
4
Filing time
13 Nov 2024, 16:57:07 UTC
Previous filing
05 Nov 2024
Next filing
26 Nov 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRNA Ordinary Shares Sale $12,000 -2,400 -0.02% $5.00 14,291,336 11 Nov 2024 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted on March 6, 2024.
F3 Consists of (i) 3,000,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 375,000 ADSs); and (ii) 11,291,336 Ordinary Shares underlying 1,411,417 ADSs.